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Bacterial adaptive immunity hinges on CRISPR-Cas
systems that provide DNA-encoded, RNA-mediated
targeting of exogenous nucleic acids. A plethora of
CRISPR molecular machines occur broadly in
prokaryotic genomes, with a diversity of Cas nucleases
that can be repurposed for various applications.chemical and structural underpinning of the ‘CRISPR-as-CRISPR-Cas systems and adaptive immunity
The characterization of biological processes that under-
lie CRISPR-based adaptive immunity in bacteria and ar-
chaea has shaped many crucial aspects of the past
decade in the fields of microbiology and genetics, and
has enabled the current ‘genome editing’ craze [1]. Clus-
tered regularly interspaced short palindromic repeats
(CRISPRs) and their CRISPR-associated (Cas) proteins
constitute the CRISPR-Cas immune system (Fig. 1),
which provides adaptive immunity against invasive ele-
ments such as viruses and plasmids in bacteria and ar-
chaea [2–5]. Although CRISPR loci were first observed
in the genome of Escherichia coli in 1987 [6], it took
15 years of microbial genomics renaissance to appreciate
their widespread occurrence in bacteria and archaea [7, 8].
Actually, it was exactly 10 years ago that the first func-
tional clue emerged, with the observation that CRISPR
spacers showed homology to viral sequences [9–11], lead-
ing to the hypothesis that they might constitute a prokary-
otic equivalent to RNA interference (RNAi) [12]. Shortly
thereafter, their biological function as adaptive immune
systems was established [13], revealing that CRISPR ar-
rays, together with cas genes, provide acquired immunity
against bacteriophages in a sequence-specific manner. The
mechanism of action of various CRISPR-Cas systems has
since been determined through milestone discoveries es-
tablishing that CRISPR-encoded immunity is mediated byCorrespondence: rbarran@ncsu.edu
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[15] and sometimes RNA [16].
Key discoveries quickly established that targeting is
generally dependent upon a short DNA sequence known
as the protospacer adjacent motif (PAM) [17–19], is
driven by seed sequences [20, 21] and is mediated by
Cas endonucleases that specifically cleave complementary
DNA [22]. For type I systems, early efforts defined the bio-
sociated complex for antiviral defence’ (Cascade) [14], and
the endonucleolytic and exonucleolytic degradation of
DNA by Cas3 [23–29]. For type II systems, early studies
defined crRNA biogenesis [30], Cas9-dependent immunity
[13] and cleavage [22], and eventually re-programmable
targeting [31] and genesis of precise double-stranded
DNA (dsDNA) breaks [32–34].
Arguably, it was the turning of native CRISPR-Cas sys-
tems into engineered and programmable two-component
systems comprising Cas9 and single guide RNAs
(sgRNAs) [33] that was the technological tipping point
that singlehandedly enabled Cas9-driven genome editing
[35–37] and fuelled the CRISPR craze that has unabatedly
unfolded since then [1, 38]. The technical tour de force es-
sentially turned the native Cas9–trans-activating CRISPR
RNA (tracrRNA)–crRNA–RNase-III four-component
system into the streamlined Cas9–sgRNA technology,
rendering the challenge of co-opting the system for
eukaryotic applications accessible. The synthetic genesis
of sgRNAs allowed the repurposing of CRISPR-Cas im-
mune systems into powerful and nimble molecular ma-
chines that can yield double-stranded breaks. Indeed, the
Cas9 molecular-scalpel-based genome editing craze was
foreshadowed in the fall of 2012 [39], following the release
of the sgRNA–Cas9 technology, and preceding the publi-
cation of proof of concept in human [35, 36] and bacterial
cells [37]. Within months, the Church, Zhang and
Marraffini labs were able to concurrently establish that
the sgRNA–Cas9 technology can be exploited for efficient
genome editing, and immediately thereafter, hundreds of
studies showed that this approach can be universallys distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 CRISPR-Cas systems and adaptive immunity. CRISPR repeats,
together with CRISPR spacers, constitute repeat-spacer arrays that
define clustered regularly interspaced short palindromic repeats
(CRISPRs). These CRISPR arrays are typically flanked by CRISPR-
associated sequences (cas) that encode Cas proteins involved in the
three stages of CRISPR-encoded immunity, namely adaptation,
expression and interference. During adaptation, Cas proteins
(including the universal Cas1 and Cas2) sample invasive DNA,
leading to the genesis of a new repeat-spacer unit that is inserted
in a polarized manner in the CRISPR array. During the second
stage — expression — the CRISPR array is transcribed into a full
pre-crRNA transcript that is processed into small, mature, interfering
CRISPR RNAs (crRNAs). In the third — interference — stage, crRNAs
guide Cas effector proteins towards complementary nucleic acids for
sequence-specific targeting. Interaction between the interference
complex and the target nucleic acid is typically initiated by binding to
the protospacer adjacent motif (PAM), which triggers interrogation of
flanking DNA by the loaded crRNA. If complementarity extends
beyond the seed sequence, an R-loop is formed, and nickase domains
within Cas effector proteins cleave the target DNA. dsDNA
double-stranded DNA, L leader
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isms. The avalanche of Cas9-based genome editing studies
attests to the potential of this broadly applicable
technology.
Mechanistically, CRISPR-Cas immunity hinges on three
distinct steps, defined as adaptation, expression and inter-
ference (Fig. 1). In the adaptation stage, CRISPR
immunization occurs through the uptake and polarized
integration of invasive DNA as a novel CRISPR spacer
into the CRISPR array, creating a serial record of vaccin-
ation events. In the expression stage, the CRISPR array is
transcribed into a full pre-CRISPR RNA (pre-crRNA)
transcript that is processed into mature crRNAs contain-
ing partial CRISPR spacer sequences attached to partial
CRISPR repeats, forming CRISPR guide RNAs. In the
interference stage, crRNAs guide Cas nucleases towards
complementary nucleic acids for sequence-specific target-
ing and cleavage of invasive genetic elements. Most
CRISPR effector proteins initiate targeting by interaction
with a particular two-to-four nucleotide sequence motif,
the PAM. Once interaction with the PAM has been estab-
lished, the crRNA guide loaded within the Cas nuclease
can then interrogate the flanking target DNA [40, 41].
The strength and duration of the molecular interaction
correlates with the level of complementarity between the
crRNA and target DNA, which drives conformational
changes in Cas effector proteins, such as Cas9 [40, 42, 43]
and Cascade [44–46], that eventually lead to a cleavage-
competent structural state [40]. If complementarity be-
tween the guide RNA and target DNA extends beyond
the seed sequence, a DNA R-loop is directionally
formed [29, 47, 48], which triggers subsequent nicking
by the Cas effector nucleases (i.e., Cas3, Cas9, Cpf1) at
particular locations defined by a ruler-anchor mechan-
ism. The literature includes many reviews that cover the
history [49–52], biology [3–5, 53–56] and applications
[57–63] of CRISPR-Cas systems.
Diversity of CRISPR-Cas systems and mechanisms
of action
In general terms, there are two main classes [64] of
CRISPR-Cas systems, which encompass five major types
and 16 different subtypes based on cas gene content, cas
operon architecture, Cas protein sequences, and pro-
cesses that underlie the aforementioned steps (Fig. 1)
[65, 66]. The first class is defined by multiprotein ef-
fector complexes (Cascade, Cmr, Csm), and encom-
passes types I, III and IV. In particular, type I systems
are the most frequent and widespread systems, which
target DNA in a Cascade-driven and PAM-dependent
manner, destroying target nucleic acids by using the sig-
nature protein Cas3 [26, 28, 67–71] (Fig. 2). Many stud-
ies have led to extensive biochemical and structural
characterization of the effector proteins and protein–
Fig. 2 (See legend on next page.)
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Fig. 2 Diversity of CRISPR-Cas molecular machines. Two main classes of CRISPR-Cas systems exist, which are defined by the nature of their Cas
effector nucleases, either constituted by multiprotein complexes (class 1), or by a single signature protein (class 2). For class 1 systems, the main
types of CRISPR-Cas systems include type I and type III systems. Illustrated here as an example, the Escherichia coli K12 type I-E system (upper left)
targets sequences flanked by a 5′-located PAM. Guide RNAs are generated by Cascade, in a Cas6-defined manner and typically contain an
eight-nucleotide 5′ handle derived from the CRISPR repeat, a full spacer sequence, and a 3′ hairpin derived from the CRISPR repeat. Following
nicking of the target strand, the 3′ to 5′ Cas3 exonuclease destroys the target DNA in a directional manner. In the Pyrococcus furiosus DSM 3638
type III-B system (lower left), a short crRNA guide directs the Cmr complex towards complementary single-stranded RNA in a PAM-independent
manner. For the canonical type II-A Streptococcus thermophilus LMD-9 system (upper right), a dual crRNA–tracrRNA guide generated by Cas9 and
RNase III targets a 3′-flanked PAM DNA complementary sequence for the genesis of a precise double-stranded break using two nickase domains
(RuvC and HNH). For the Francisella novicida U112 type V system (lower right), a single guide RNA targets complementary dsDNA flanked by a
5′-PAM using Cpf1, which generates a staggered dsDNA break. Cascade CRISPR-associated complex for antiviral defense, CRISPR clustered regularly
interspaced short palindromic repeat, crRNA CRISPR RNA, dsDNA double-stranded DNA, L leader, nt nucleotide, PAM protospacer adjacent motif,
ssRNA single-stranded RNA, tracrRNA trans-activating CRISPR RNA
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systems [20, 23, 24, 46, 72–77]. Likewise, type III sys-
tems occur frequently in archaea and are characterized
by the multiprotein Csm [78–82] or Cmr [16, 83–95]
complexes; they operate in a PAM-independent manner
and can cleave DNA or RNA by using the signature
Cas10 protein together with effector nucleases such as
Cmr4 (the RNase within the Cmr complex for type III-B
systems) [85, 95] and Csm3 (the RNase within the Csm
complex for type III-A systems) [81, 82]. Interestingly,
several recent studies have revealed that type III
CRISPR-Cas systems can actually target both nucleic
acid types, through co-transcriptional RNA and DNA
cleavage [80, 82]. Specifically, distinct active sites within
the Cas10–Csm ribonucleoprotein effector complex
drive co-transcriptional RNA-guided DNA cleavage and
RNA cleavage [80]. Type IV systems are rather rare and
still remain to be characterized in terms of their distri-
bution and function.
By contrast, the second class is defined by single ef-
fector proteins and encompasses types II and V. Type II
systems are defined by the popular Cas9 endonuclease
[22], which hinges on dual crRNA–tracrRNA guides
[30] that direct the RuvC and HNH nickase domains to
generate precise blunt DNA breaks in target DNA se-
quences flanked by a 3 PAM [22, 31–34, 96, 97]. Type
V systems are rare, and characterized by the signature
Cpf1 nuclease, which is guided by a single crRNA that
directs this RuvC-like endonuclease for staggered
dsDNA nicking to yield sticky-ends in target DNA se-
quences flanked by a 5′ PAM [98].
Recently, several studies have shown that, although
CRISPR-Cas systems generally function in three distinct
stages, involving peculiar molecular processes and various
Cas molecular machines, the adaptation and interference
steps can actually be coupled [48, 99–101], which is con-
sistent with the priming hypothesis [48, 102–104]. Specif-
ically, differential binding determines whether cognate
target DNA should be destroyed as part of the inter-
ference pathway, or whether partially complementarysequences should be directed towards the adaptation
path [48]. The coupling of the adaptation and interfer-
ence stages also reflects their co-dependence on Cas9
and PAM sequences in type II systems [100, 101, 105],
and implicates a ‘cut-and-paste’ model rather than ‘copy
and paste’ [100].
Overall, a broad genetic and functional diversity of
CRISPR-Cas immune systems occurs in the genomes of
many bacteria and most archaea. Common denomina-
tors include DNA-encoded immunity within CRISPR
arrays that yield small guide RNAs, which define
sequence-specific targets for Cas nucleases and subse-
quent nucleic acid cleavage. The universal cas1 and cas2
genes, implicated in polarized, sequence- and structure-
specific integrase-mediated spacer acquisition during the
adaptation stage [106–108], are present in all character-
ized types and subtypes in the two main classes. By con-
trast, there is substantial variability between classes,
types and subtypes concerning the nature, sequence and
structure of the CRISPR RNAs and Cas proteins in-
volved, the reliance on and location of PAM sequences,
and the nature of the target nucleic acid. Altogether, this
illustrates the extensive multi-dimensional diversity of
CRISPR-Cas systems, their native biological functions,
and the relative potential for various biotechnological
and industrial applications.
The diversity of CRISPR-Cas systems reflects their
various functional roles. Although the primary estab-
lished function of CRISPR-Cas systems is adaptive
immunity against invasive genetic elements such as plas-
mids and viruses, several studies have independently
implicated them in other functions, including endogen-
ous transcriptional control, as well as resistance to
stress, pathogenicity and regulation of biofilm formation
[63, 109–114].
Future studies are anticipated to determine the ration-
ale for the distribution biases in various phylogenetic
groups, for the absence of CRISPR-Cas systems in so
many bacteria, and to unravel the functional links be-
tween immunity and other key biological processes such
Fig. 3 Applications and targets of CRISPR-Cas systems. CRISPR-Cas
systems can target various types of nucleic acids, including invasive
and mobile DNA (green box), or endogenous sequences (blue box).
In their native environment, CRISPR-Cas systems naturally target
mobile and exogenous DNA elements. Conversely, engineered systems
are typically designed to target self-DNA to trigger endogenous
modifications. Targeting can be directed at bacteriophage DNA
to provide anti-viral defense (upper left). Likewise, Cas nucleases
can be directed at plasmid DNA in order to prevent uptake and
dissemination of undesirable sequences or to cure the host of
plasmid sequences (center left). Targeting can also be directed at
mobile DNA elements such as transposons so as to maintain
DNA integrity and ensure homeostasis (lower left). When aiming
the CRISPR-Cas machinery towards the cell’s own chromosomal
content, the purpose is typically to induce endogenous DNA repair
pathways to drive editing of the DNA sequence (upper center).
Catalytically deactivated variants of Cas nucleases can be used as
DNA-binding proteins to block transcription (CRISPRi, upper right), or
can be fused to transcriptional activators to activate transcription
(CRISPRa, center right). Alternatively, Cas nucleases can be reprogrammed
to trigger a lethal auto-immune response, leading to cell death
(bottom right). CRISPR sequences themselves can be used for
genotyping, by using the series of vaccination events as a genetic
historical record (lower center). Cas CRISPR associated, CRISPR
clustered regularly interspaced short palindromic repeat, CRISPRa
CRISPR activation, CRISPRi CRISPR interference
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drum about CRISPR-Cas systems is their absence in ap-
proximately half of the bacterial genomes sequenced to
date, despite their intuitive evolutionary value. Another
important consideration is whether the observed biases
in proto-spacer sampling during adaptation correlate
with efficiency biases for the interference stage. Specific-
ally, spacer adaptation biases have been repeatedly ob-
served in type I systems [115, 116] and in type II
systems [105, 117], implicating replication-dependent
DNA breaks at replication forks, Chi sites and interplay
with the RecBCD DNA repair machinery, and so it will
be important to determine whether these also explain
spacer efficiency variability during interference.
Applications of native and engineered CRISPR-Cas
systems in bacteria
Although the large majority of the CRISPR literature fo-
cuses on genome editing applications in eukaryotes,
CRISPR-Cas systems arguably afford the most applica-
tions in both native and engineered forms in bacteria
[118, 119]. Actually, most of the alleged CRISPR litera-
ture does not employ bona fide clustered regularly inter-
spaced short palindromic repeats, but instead features
crRNA-guided Cas9 proteins. Given the aforementioned
CRISPR-Cas system diversity, and the available molecu-
lar biology tools for bacteria, we are thus on the cusp of
full exploitation in microbes. There are three primary
ways to harness CRISPR-Cas systems, depending on the
CRISPR immunity stage, Cas machinery and outcome
being exploited (Fig. 3).
First, the outcomes of native vaccination events can be
used to genotype bacteria by comparing and contrasting
the spacer acquisition events to unravel the evolutionary
path of a strain isolate, or to delve into assessing the
genetic composition and diversity of a population (Fig. 3).
This approach has proven valuable for the typing of bac-
terial pathogens in which CRISPR array diversity reflects
functional acquisitions over time, such as in Escherichia
coli, Yersinia pestis, Mycobacterium tuberculosis, Sal-
monella enterica and Clostridium difficile [120]. This
method is also instrumental for the detection and moni-
toring of industrially valuable workhorses associated with
bioprocessing and food manufacturing, such as probiotics
and starter cultures [17, 121–124]. Similar approaches, in
combination with deep sequencing technology, have
shown tremendous potential for the analysis of complex
microbial populations, for the determination of clonal
population diversity, and for the analysis of co-
evolutionary dynamics and arms-races between bacteria
and phages [105, 117, 125–127]. Studies can specifically
investigate the evolutionary dynamics of hosts and phage
populations and unravel selection events and counter-
selective mutational patterns that allow bacteria to thrivein inhospitable conditions [128, 129]. In fact, early meta-
genomic work on CRISPR diversity and interplay with
phage sequences from the Banfield laboratory was crucial
in establishing the CRISPR field [130, 131]. More recently,
studies of CRISPR-based interplay between bacteria and
viruses have expanded to human-associated microbial
populations, including in the oral cavity and gastrointes-
tinal tract [132–135].
Second, CRISPR-Cas immune systems can be used to
vaccinate against invasive genetic elements [13]. Either
naturally or by engineering, CRISPR-Cas systems can be
exploited to provide resistance against phages [136] or
preclude uptake and dissemination of undesirable gen-
etic material such as antibiotic resistance genes [22] or
Barrangou Genome Biology  (2015) 16:247 Page 6 of 11possibly target mobile genetic elements such as transpo-
sons to ensure genome homeostasis. In addition to
blocking bacteriophages, CRISPR interference is a potent
barrier to natural DNA transformation that can be har-
nessed to prevent the acquisition of virulence traits
[137]. Perhaps surprisingly, the industrial exploitation of
CRISPR-Cas systems for the genesis of robust and
sustainable starter cultures used for the manufactur-
ing of fermented dairy products has been imple-
mented commercially in consumer products for several
years [120, 136, 138]. Actually, exploiting first-generation
CRISPR patent applications that are over a decade old,
and building off early scientific discoveries about adaptive
spacer acquisition in Streptococcus thermophilus, naturally
generated bacteria that have been screened for vaccination
events against phage isolated from commercial settings
have been exploited on a global scale since 2011. Of
course, natural CRISPR-immunized strains might have
been used for a long time, unbeknownst to us. Practically,
the breadth and depth of phage resistance can be built up
iteratively through multiple rounds of selection of natural
vaccination events that eventually yield a sustainable
starter culture with increased life span in the food indus-
try. Similar approaches hold much potential for the im-
provement of industrial workhorses valuable to the bio-
manufacturing industry.
Third, endogenous or engineered Cas machinery can
be repurposed for self-DNA targeting in a wide range of
applications that encompass genome editing and tar-
geted killing (Fig. 3). Many studies have documented the
nimble potential of the sgRNA–Cas9 technology for
‘traditional’ genome editing, to knock out, insert or
delete genes [57–59]. Furthermore, deactivated versions
of Cas9 (dCas9) have been generated by inactivation of
the RuvC and HNH nickase domains to turn the nucle-
ase into a DNA binding protein able to control tran-
scription, either by blocking RNA polymerases (CRISPR
interference, CRISPRi) or by promoting transcription
when tethered to transcriptional activators (CRISPR acti-
vation, CRISPRa). The use of both endogenous and engi-
neered CRISPR-Cas systems for transcriptional control
in bacteria has already been documented [139–141].
More recently, functional variants of Cas9 associated
with fluorophores or methylase domains have been used
for imaging and epigenome modification [142, 143], re-
spectively. These applications have redefined genome
editing beyond the alteration of the DNA sequence per
se, and now enable the editing of any sequence in any
cell in many ways. Despite the Cas9-based genome edit-
ing bias in eukaryotes, their implementation in bacteria
is on the rise [118, 144–147]. In bacteria, a promising re-
cent application of self-targeting is programmable killing
[148], opening new avenues for the genesis of next-
generation smart antimicrobials based on variousCRISPR-Cas systems [148–152]. Specifically, engineered
Cas9 systems, as well as native Cas9 and Cascade
machines, have been successfully re-programmed for
sequence-specific targeted killing of a bacterial population,
which allows the manipulation of mixed consortia, and
the select eradication of defined genotypes of interest
[148]. This has successfully been implemented to target E.
coli, Streptococcus and Staphylococcus aureus, both in
in vitro and in vivo models [148–151]. This is an oppor-
tunity to properly select and leverage particular CRISPR-
Cas systems that might be better suited for efficient kill-
ing, such as type I systems that rely on the Cas3 endo-
and exo-nuclease, which digests the target DNA following
initial cleavage (Fig. 2), and thus affords the cell fewer op-
portunities to repair cleaved DNA. Moving forward, there
is much potential for this technology to develop narrow-
range antibiotics that can be customized for the alteration
of microbiomes. This also opens intriguing prospects for
programmable eradication of select cell populations in
eukaryotes.
Altogether, these various applications illustrate the
functional diversity of CRISPR-Cas systems (Fig. 3) and
set the stage for the customized selection and develop-
ment of various molecular machines to expand the mo-
lecular biology toolbox. In some ways, type I systems
can be construed as a powerful ‘hammer’, which heavily
hits and destroys target DNA with the Cas3 exonuclease.
Type II systems could be used as nimble ‘screwdrivers’,
which precisely target DNA with the Cas9 endonuclease.
Similarly, the recently characterized type V systems [64]
can be perceived as screwdrivers with a different pro-
pensity (flat-head versus phillips) for precise targeting of
DNA with the Cpf1 endonuclease [98]. Type III systems
can be employed as ‘box cutters’ that can cleave either
DNA or RNA with the signature Cas10 nuclease. Given
how much our understanding of system diversity has in-
creased in the past 15 years, the diversity of CRISPR-Cas
systems will predictably further increase as we deepen
our knowledge of microbial genomics, and valuable Cas
molecular machines might be unearthed in the future.
Altogether, these native and engineered systems hold
tremendous potential for a broad range of bacterial ap-
plications (Fig. 4).
Keep calm and CRISPR on
Although the advent of the sgRNA–Cas9 technology for
eukaryotic genome editing is merely two years old, the
success of this disruptive technology is undeniable [1, 38].
It is noteworthy to point out that the scientific commu-
nity was primed for the use and rapid implementation
of this technology, given the historical use of the power-
ful RNAi technology on the one hand, and the rise of
TALEN-, meganuclease- and zinc-finger nuclease
(ZFN)-based genome editing applications on the other.
Fig. 4 Exploitation of endogenous and engineered CRISPR-Cas systems in bacteria. Exogenous DNA sequences can be targeted by CRISPR-Cas
systems to build up phage resistance in food starter cultures (to vaccinate yoghurt strains against bacteriophage), to prevent the uptake and
dissemination of plasmids that encode undesirable traits such as antibiotic resistance genes (to immunize probiotic strains used in dietary supplements),
or to ensure the genetic integrity and genomic homeostasis of valuable cultures (to fend off mobile genetic elements such as transposons and
prophages) (upper panels). Unique records of iterative vaccination events captured as a series of spacers in CRISPR arrays can be used as
sequencing targets for the detection, monitoring and typing of strains of interest, which include food cultures, spoilage organisms or pathogens
(center panels). By contrast, self-targeting and engineered applications can be used in industrial settings to improve industrial workhorses by
genome editing (indicated by ‘scissors’ symbol), or by re-directing the metabolic flux of various pathways for synthetic and yield purposes
(lower panels). Lethal self-targeting can also be harnessed for the select eradication of pathogens or contaminants of interest. CRISPRa CRISPR
activation, CRISPRi CRISPR interference
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eager, to unleash the potential of this powerful technol-
ogy. In hindsight, there are many attributes of CRISPR-
Cas systems that render them valuable, including
programmability, transferability, efficiency, specificity,
affordability, rapidity of implementation, precision, ease
of use, and ability to multiplex both guides and systems.
Nevertheless, this is still a nascent technology, which
needs improvements, especially as it relates to size
(Cas9 is arguably cumbersome), targeting flexibility
(broadening the PAM space) and efficiency (ability to
recognize and cleave targets with specificity and effi-
ciency). Perhaps a longer-term improvement consists of
being able to select the most efficient spacer sequences
since not all CRISPR spacers or RNA guides provide
equal targeting of phage or target sequences, respect-
ively, and adequate prediction of common outcomes
(ability of viruses to mutate targeted sequences, or pro-
pensities of various DNA repair pathways to alter the
cleaved sites). Already, biochemical and structuralinsights [43, 153–157] are fuelling efforts under way to
engineer guides and Cas nucleases for improved
functionalities, including smaller variants and PAM-
targeting flexibility. In parallel, analysis of Cas nuclease
diversity and orthogonality [156, 158–162] will acceler-
ate the rational design of next-generation engineered
nucleases. Likewise, lessons from RNAi are instrumental
in optimizing the composition and structure of functional
CRISPR guides for improved activity and specificity. Fi-
nally, the characterization of additional CRISPR-Cas sys-
tems in general, and more Cas effector proteins in
particular, will broaden the set of forthcoming molecu-
lar tools available for various applications.
Already, there are a few valuable lessons regarding Cas
effector proteins that have been gathered from CRISPR
applications in bacteria that could prove useful to the
broad scientific community. In particular, it is note-
worthy to point out that, per se, immune systems must
afford both specificity and efficiency, so as to prevent
auto-immunity and ensure survival, respectively. This is
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speed with which phage co-opt the host cellular machin-
ery, and the ease with which they can mutate to escape
sequence-specific targeting. Indeed, stealth and specific
targeting of viral DNA occurs through Cas effector pro-
tein recognition of bona fide sequences, and their spe-
cific nucleolytic destruction. CRISPR-based eradication
of phages and toxic DNA thus occurs on the scale of mi-
nutes following infection, ensuring efficiency. Likewise,
targeting hinging on protospacer recognition ensures
that lethal self-targeting events are avoided, providing
specificity.
Using recent history and the current momentum to
foretell the short-term future of the CRISPR craze, it ap-
pears that: first, the pace at which the field is moving
forwards is not abating, as indicated by literature output,
citation rates and funding trends; second, the coverage
has extended feverishly beyond the scientific press, into
the mass media; and finally some of the most enthralling
level of interest lies in the business commitment and
commercial potential of that technology, illustrated by
financial investment levels spanning a broad range of
business segments, such as medicine, food, agriculture
and biotechnology. As the fascinating CRISPR story con-
tinues to unfold, and the IP, ethical and awards debates
consume attention, it will be crucial to ensure that we
keep calm and CRISPR on to ensure we do not hinder
but, instead, unleash and further advance this powerful
technology.
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